Entrada Therapeutics, Inc. (TRDA) financial statements and ratios from SEC XBRL: revenue $25.42M (TTM), net margin -565.5%, revenue growth -87.9% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $25.42M |
| Net Margin | -565.5% |
| Revenue Growth (YoY) | -87.9% |
| EPS Growth (YoY) | -297.2% |
| FCF Growth (YoY) | 189.7% |
| Price / Book | 1.09 |
| Price / Sales | 11.79 |
| FCF Yield | -84.3% |
| Altman Z-Score | 1.02 (distress) |
| Sector P/E (Healthcare) | 21.7 |
TRDA overview · TRDA earnings · TRDA KPIs · TRDA investor relations · TRDA ownership · TRDA peers · TRDA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.